Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH +1.89%87 Equity-to-Asset is 0.74 as of Mar. 2026, which is 1% below its 10-year median of 0.75. GuruFocus rates ASX:FPH with a GF Score™ of 87/100 and a GF Value™ of A$36.80 (Fairly Valued). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 65.06% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's Equity-to-Asset or its related term are showing as below:
ASX:FPH'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.68 Med: 0.75 Max: 0.8
Current: 0.74
During the past 13 years, the highest Equity to Asset Ratio of Fisher & Paykel Healthcare was 0.80. The lowest was 0.68. And the median was 0.75.
ASX:FPH's Equity-to-Asset is ranked better than 65.06% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ASX:FPH: 0.74
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Fisher & Paykel Healthcare Equity-to-Asset Related Terms
Fisher & Paykel Healthcare Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Fisher & Paykel Healthcare's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Equity-to-Asset of 0.74 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 0.75. Over the past decade, Fisher & Paykel Healthcare's Equity-to-Asset has ranged from 0.68 to 0.80. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #298 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 34.9%.
Is Fisher & Paykel Healthcare's Equity-to-Asset too high?
Fisher & Paykel Healthcare's current Equity-to-Asset of 0.74 is near median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 0.80. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Fisher & Paykel Healthcare's value of 0.74 is 15.6% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #298 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #298 out of 853 companies for Equity-to-Asset. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median Equity-to-Asset is 0.64. Fisher & Paykel Healthcare's value of 0.74 is 15.6% above this benchmark. Historically, Fisher & Paykel Healthcare's own Equity-to-Asset has ranged from 0.68 to 0.80 over the past decade. While the company's 10-year median is 0.75 vs. the industry median of 0.64, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Equity-to-Asset of 0.74 is 15.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Equity-to-Asset is 0.74, which is near median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.80, compared to a current price of A$35.13 — trading 4.5% below its estimated fair value. The current Equity-to-Asset is 0.74, which is near median its 10-year median of 0.75 and 15.6% above the Medical Devices & Instruments industry median of 0.64. Fisher & Paykel Healthcare's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Equity-to-Asset is 0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$35.13 is trading 4.5% below its estimated GF Value™ of A$36.80.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
Equity-to-Asset: 0.74 (near median its 10-year median of 0.75)
GF Value™: A$36.80 vs. price of A$35.13 (4.5% below fair value)
Industry Position: 15.6% above the Medical Devices & Instruments median (#298 of 853)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
87GF Score
Get the complete analysis for ASX:FPH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
